Gardner, MA – New England Peptide, LLC, (NEP) has named Dr. Ved Srivastava as its new Vice President for research production. Srivastava, who most recently served as associate director of discovery research at Amylin Pharmaceuticals, Inc., was also a member of NEP’s Scientific Advisory Board.
In his new role as VP of research production, a newly-created position, Srivastava will be responsible for overseeing NEP’s entire production pipeline.
“Ved is a tremendous addition to the New England Peptide’s daily operations,” said NEP’s CEO Dave Robinson. “With his decades of experience in peptides and his intimate knowledge of NEP through his service on our SAB, Ved has already hit the ground running.”
While at Amylin, Srivastava led the peptide chemistry core team with a focus in discovery, synthesis and development of novel peptide hormones for diabetes, obesity and neuropsychiatric therapies. He also directed research chemistry team of Psylin Neurosciences, Inc., a biotech company formed as a joint venture between Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. With more than 20 years of experience in drug discovery, and inflammation and metabolic diseases, Srivastava has focused primarily in medicinal and peptide chemistry. He is a frequently cited journal author, a councilor of the American Chemical Society, and a two-time recipient of the section’s Outstanding Service Award.
Srivastava earned a doctoral degree in organic chemistry from the University of Lucknow in India. Post-doctoral appointments included posts at the University of Georgia and the medical school at the University of Colorado, where he worked under John Stewart, Ph.D.
“I am excited to join New England Peptide. NEP is committed to innovation in peptide technology and to provide the highest levels of quality service," said Srivastava. "I am also very impressed with the entire team at NEP, and I look forward to contributing to achieving our strategic goals."
Srivastava is one of many talented peptide professionals NEP has brought aboard in recent months. In December, NEP named award winning peptide research expert Dr. Robert Hammer as its vice president of chemical development. Hammer and new SAB members Dr. Robert Hodges, are leading NEP’s transition to the use of alternative solvents amid a global shortage of acetonitrile. Dr. Vincent Bille, Dr. Tomi Sawyer and Dr. Victor Hruby are the other members of the SAB, which was formed in October.
“This really is an exciting time for all of us at New England Peptide,” said Robinson. “Our team has the right blend of experience and innovative thinking that will allow us to develop dependable products and new solutions to help our customers in their critical research endeavors.”
About New England Peptide (www.newenglandpeptide.com)
New England Peptide, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.
Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides’ inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use. All segments of the peptide market – from therapeutics and vaccines to diagnostics and cosmetics – are thriving.